CGRP inhibitors did not increase glaucoma risk in a large cohort of patients with migraine, according to findings published in Neurology.“Migraine and glaucoma have been linked through shared neurovascular mechanisms, and CGRP plays a central role in migraine pathophysiology while also being present in ocular tissues,” Chien-Hsiang Weng, MD, MPH, FAAFP, clinical associate professor at the Alpert Medical School of Brown University, told Healio.“With the rapid uptake of CGRP inhibitors in clinical practice, we wanted to examine whether targeting this pathway might have downstream effects on